Results 141 to 150 of about 41,988 (210)

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study

Movement Disorders, EarlyView.
Abstract Background Although not confirmed, some studies have suggested that elevated homocysteine levels are common in patients with Huntington's disease (HD). Its clinical relevance remains unclear. Objectives We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B ...
Salomé Puisieux, Elise Pourié, Céline Bonnet, Lucie Hopes, Solène Frismand, Myriam Bronner, Virginie Roth, Marion Wandzel, Natacha Sloboda, Laetitia Lambert, Abderrahim Oussalah, Amélia Julien, Irina Rotaru, Rosa‐Maria Guéant‐Rodriguez, Jean Louis Guéant, Carine Bossenmeyer‐Pourié, Mathilde Renaud   +16 more
wiley   +1 more source

Antipsychotic medication for childhood-onset schizophrenia [PDF]

, 2007
Datta, Soumitra, Kumar, Ajit, Kennedy, Eilis   +2 more
core   +1 more source

Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records

Movement Disorders, EarlyView.
Abstract Background Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population‐level evidence on its effect on PD risk is lacking. Objectives To compare the risk of incident PD among UDCA initiators versus matched non‐initiators within a ...
Chengsheng Ju, Anette Schrag, Camille Carroll, Xi Xiong, James Carpenter, Oliver Bandmann, Thomas Foltynie, Li Wei   +7 more
wiley   +1 more source

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

ClinicoEconomics and Outcomes Research
Christopher Zacker,1 Justin T Puckett,2 Sachin Kamal-Bahl2 1Cerevel Therapeutics, LLC, Cambridge, MA, USA; 2COVIA Health Solutions, Ambler, PA, USACorrespondence: Sachin Kamal-Bahl, COVIA Health Solutions, 915 Brewster Lane Ambler, PA 19002, Tel +1 267 ...
Zacker C, Puckett JT, Kamal-Bahl S
doaj  

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia

, 2009
Xinhua S Ren1,2,3, Lawrence Herz4,5, Shirley Qian1,2,3, Eric Smith3,4, Lewis E Kazis1,2,31The Center for the Assessment of Pharmaceutical Practices (CAPP), Boston University School of Public Health, Boston, MA, USA; 2Department of ...
Xinhua S Ren, Shirley Qian, et al, Lawrence Herz   +3 more
core  

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Artemia salina Toxicity Assay: Standardization in a 24‐Well Microplate

Environmental Toxicology, EarlyView.
ABSTRACT Bioassays with Artemia sp. are widely used in aquatic, environmental, and human toxicology as an initial tool to investigate the toxicity of plant extracts, isolated compounds, drugs, and products of natural or synthetic origin. These assays allow for the estimation of the median lethal concentration (LC50) and guide subsequent studies in ...
Matheus Pires Miranda, Natalie Petrovna Semanovschi, Roseane Santos de Souza, Angélica Maria Lucchese, Luzimar Gonzaga Fernandez   +4 more
wiley   +1 more source

Risk of Antipsychotic Initiation Among Older Dementia Patients Initiating Cholinesterase Inhibitors [PDF]

Soumya G Chikermane, Jieni Li, Rajender R Aparasu University of Houston, College of Pharmacy, Department of Pharmaceutical Health Outcomes and Policy, Houston, TX, USACorrespondence: Rajender R Aparasu, Department of Pharmaceutical Health Outcomes and ...
Chikermane SG, Aparasu RR, Li J
core  

Opening the Door Wider to Community Support of People With Serious Mental Illnesses: What States Can Learn From the IDD Experience

The Milbank Quarterly, EarlyView.
Policy Points The federal government should provide states with authorities under Medicaid that allow greater use of home and community‐based services for people with serious and persistent mental illness. This requires deemphasizing authorities that require budget neutrality in a post‐institutionalization world (Section 1115 waivers) and relying on ...
HAROLD POLLACK, RICHARD FRANK, SHERRY GLIED   +2 more
wiley   +1 more source